1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Mersana Therapeutics Inc (MRSN)
  7. Quote


Mersana Therapeutics Stock Price

0.02 (0.24%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Mersana Therapeutics Inc MRSN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.02 0.24% 8.49 18:00:02
Open Price Low Price High Price Close Price Prev Close
8.87 8.44 8.87 8.49 8.47
Bid Price Ask Price Spread News
8.48 8.90 0.42 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,464 903,811 $ 8.72 $ 7,877,864 - 8.25 - 29.09
Last Trade Time Type Quantity Stock Price Currency
17:01:16 5 $ 8.50 USD


Draw Mode:

Mersana Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 609.26M 71.76M 62.96M $ 17.55M $ - -1.44 -4.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 209.04k 1.40%

more financials information »

Mersana Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MRSN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week9.,650-0.52-5.77%
1 Month9.7110.068.259.22529,451-1.22-12.56%
3 Months11.9014.808.2510.69806,874-3.41-28.66%
6 Months17.0817.568.2512.37669,081-8.59-50.29%
1 Year18.8729.098.2517.17814,426-10.38-55.01%
3 Years8.3429.091.3214.99671,1490.151.8%
5 Years14.2529.091.3214.99506,993-5.76-40.42%

Mersana Therapeutics Description

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.

Your Recent History
Mersana Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.